{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:04:37Z","timestamp":1789473877080,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology Case Reports"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eucr.2026.103570","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T23:52:41Z","timestamp":1786492361000},"page":"103570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Neoadjuvant lenvatinib and pembrolizumab for metastatic clear cell renal cell carcinoma: A potential opportunity for complete pathologic and radiographic response"],"prefix":"10.1016","volume":"68","author":[{"given":"Eva Kiri","family":"Walker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Yau","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Aron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monish","family":"Aron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.eucr.2026.103570_bib1","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jama.2024.12848","article-title":"Renal cell carcinoma: a review","volume":"332","author":"Rose","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eucr.2026.103570_bib2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/bju.13349","article-title":"Extent of renal vein invasion influences prognosis in patients with renal cell carcinoma","volume":"118","author":"Ball","year":"2016","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.eucr.2026.103570_bib3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.eucr.2026.103570_bib4","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"issue":"9637","key":"10.1016\/j.eucr.2026.103570_bib5","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.eucr.2026.103570_bib6","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.eucr.2026.103570_bib7","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.eucr.2026.103570_bib8","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.eucr.2026.103570_bib9","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.eucr.2026.103570_bib10","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.eucr.2026.103570_bib11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eucr.2026.103570_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.70349","article-title":"Global patterns and trends in kidney cancer incidence and mortality","author":"Barchuk","year":"2026","journal-title":"Int J Cancer"},{"issue":"2 Pt 1","key":"10.1016\/j.eucr.2026.103570_bib13","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/01.ju.0000074870.54671.98","article-title":"Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas","volume":"170","author":"Na","year":"2003","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.eucr.2026.103570_bib14","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1200\/JCO.2013.50.3961","article-title":"Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma","volume":"32","author":"Hutson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.eucr.2026.103570_bib15","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.eucr.2026.103570_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1470-2045(23)00049-9","article-title":"Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eucr.2026.103570_bib17","article-title":"Effectiveness, toxicity and treatment adjustments of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: a multicenter real-world analysis","volume":"8","author":"Stelmach","year":"2025","journal-title":"ESMO Real World Data Digit Oncol"},{"issue":"3","key":"10.1016\/j.eucr.2026.103570_bib18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/iju5.12584","article-title":"A case of metastatic renal cell carcinoma successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy","volume":"6","author":"Sato","year":"2023","journal-title":"IJU Case Rep"},{"issue":"1","key":"10.1016\/j.eucr.2026.103570_bib19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/iju5.12668","article-title":"Cine magnetic resonance imaging predicts thrombus adhesion in metastatic renal cell carcinoma with an inferior vena cava tumor thrombus: a case of pathological complete response with pembrolizumab plus lenvatinib","volume":"7","author":"Hara","year":"2024","journal-title":"IJU Case Rep"}],"container-title":["Urology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214442026002330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214442026002330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:33:47Z","timestamp":1789472027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214442026002330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":19,"alternative-id":["S2214442026002330"],"URL":"https:\/\/doi.org\/10.1016\/j.eucr.2026.103570","relation":{},"ISSN":["2214-4420"],"issn-type":[{"value":"2214-4420","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant lenvatinib and pembrolizumab for metastatic clear cell renal cell carcinoma: A potential opportunity for complete pathologic and radiographic response","name":"articletitle","label":"Article Title"},{"value":"Urology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eucr.2026.103570","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103570"}}